Telara Pharma - focused and committed to kidney disease improvement.

focused and committed to kidney disease improvement.

Home
Science
Pipeline
About Us
News

Monthly Archives: April 2024

Telara Pharma > News > 2024 > April

01

Apr

Date April 1, 2024

Author TelaraPharma

Telara Pharma awarded €841.000 from Spanish government to characterize the mechanism of action of cilastatin to act as a preventive treatment in acute and chronic inflammatory indications

Telara Pharma (Lead coordinator, Madrid, Spain), Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIB...

Author TelaraPharma

Search for:

Categories

Arch Biopartners 3
Award 2
TelaraPharma 9

Recent Posts

Our CSO Dr. Alberto Lázaro publishes a Commentary in the Kidney International Journal about CilastatinSeptember 23, 2024
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsAugust 2, 2024
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug ProductJune 27, 2024
Telara Pharma awarded €841.000 from Spanish government to characterize the mechanism of action of cilastatin to act as a preventive treatment in acute and chronic inflammatory indicationsApril 1, 2024
Telara Pharma has been awarded a €325,000 non-refundable grant through the Spanish Ministry of Science and Innovation Neotec programme, managed by the Centre for the Development of Industrial Technology (CDTI).April 5, 2023

Tags

Arch Biopartners Dr. Alberto Lázaro Dr. Alberto Tejedor GENESIS Biomed Gregorio Marañon IiSGM renal injury The Cilastatin project

Archives

September 2024
August 2024
June 2024
April 2024
April 2023
June 2021
May 2021
April 2021
November 2020

Telara Pharma is a global leader in repurposing the drug cilastatin to make new therapies for severe inflammatory disorders like Acute Kidney Injury (AKI).

Menu

Home
Pipeline
About Us
News
Contact

SCIENCE

Problem
Solution
Specific Data
Papers

RECENT POST

Our CSO Dr. Alberto Lázaro publishes a Commentary in the Kidney International Journal about Cilastatin September 23, 2024
Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins August 2, 2024

Copyright © 2024 TelaraPharma. All rights reserved.